Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

Journal of Virology

Volumn 72, Issue 5, 1998, Pages 3773-3778

  Harrigan, P Richard ^a,b   Bloor, Stuart ^a,c   Larder, Brendan A ^a,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c Virco UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; DOSE RESPONSE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0031958266     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.5.3773-3778.1998     Document Type: Article

References (28)

1. Albert, J., J. Wahlberg, J. Lundeberg, S. Cox, E. Sandstrom, B. Wahren, and M. Uhlen. 1992. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J. Virol. 66:5627-5630.
2. Boucher, C. A., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Boucher, C. A., R. van Leeuwen, P. Kellam, P. Schipper, J. Tijnagel, J. M. Lange, and B. A. Larder. 1993. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1525-1530.
4. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
5. Dimitrov, D. S., R. L., Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:2182-2190.
6. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
7. Goudsmit, J., A. de Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5666.
8. Gurusinghe, A. D., S. A. Land, C. Birch, C. McGavin, D. J. Hooker, G. Tachedjian, R. Doherty, and N. J. Deacon. 1995. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J. Med. Virol. 46:238-243.
9. Harrigan, P. R., I. Kingdom, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
10. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
11. Holland, J. J., J. C. de la Torre, D. K. Clarke, and E. Duarte. 1991. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 65:2960-2967.
12. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:8010-8018.
13. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
14. Kellam, P., C. A. Boucher, J. M. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
15. Kellam, P., and B. A. Larder. 1995. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:669-674.
16. Kuritzkes, D. R. 1996. Clinical significance of drug resistance in HIV-1 infection. AIDS 10(Suppl. 5):S27-S31.
17. Larder, B. A. 1995. Viral resistance and the selection of antiretroviral combinations. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 1):S2S-S33.
18. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
19. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
20. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronick, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
21. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
22. McDonald, C. K., and D. R. Kuritzkes. 1997. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:951-959.
23. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
24. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
25. Rooke, R., M. Tremblay, H. Soudeyns, L DeStephano, X. J. Yao, M. Fanning, J. S. Montaner, M. O'Shaughnessy, K. Gelmon, C, Tsoukas, and the Canadian Zidovudine Multi-Centre Study Group. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3:411-415.
26. Smith, M. S., K. L. Koerber, and J. S. Pagano. 1994. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J. Infect. Dis. 169:184-188.
27. Wainberg, M. A. 1997. Reverse transcriptase fidelity and HIV-1 variation. Science 275:229-230.
28. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.